Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05174351 · ClinicalTrials.gov registry record · NA
Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction
A NA study of Heart Failure With Preserved Ejection Fraction, sponsored by UConn Health.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05174351: Recruiting NA study of Heart Failure With Preserved Ejection Fraction, sponsored by UConn Health.
NCT05174351 is a NA study of Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by UConn Health. The registered enrollment target is 30 participants, below the 2,288-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05174351, a NA study of Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by UConn Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective pilot study to evaluate changes before and 4 weeks after beta-blocker withdrawal in 30 HFpEF patients.
Primary Outcome
Kansa city cardiomyopathy questionnaire (KCCQ-23)- self-administered, 23-item. questionnaire that quantifies physical limitations, symptoms, self-efficacy, social interference and quality of life. Scores are transformed to a range of 0-100, where higher scores reflect better health status.
Conditions Studied
Interventions
- OTHER beta blocker discontinuation
Study Locations (1)
Connecticut
- UConn Health / John Dempsey Hospital - Farmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-12-20 |
| Est. Completion | 2027-11-01 |
| Phase | NA |
What NCT05174351 shows while recruiting
NCT05174351 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 2,288-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which beta blocker discontinuation is the first listed.
NCT05174351 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05174351 about?
NCT05174351 is a clinical study titled "Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction". This is a prospective pilot study to evaluate changes before and 4 weeks after beta-blocker withdrawal in 30 HFpEF patients.
What is the current status of trial NCT05174351?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2021-12-20. Estimated completion is 2027-11-01.
What conditions does trial NCT05174351 study?
This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction.
What interventions are being tested in trial NCT05174351?
The interventions under investigation include: beta blocker discontinuation (OTHER).
Who is sponsoring clinical trial NCT05174351?
This trial is sponsored by UConn Health, which has 178 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05174351 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure With Preserved Ejection Fraction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05174351's enrollment target sits among peer trials
30 31st of 42 higher than 9 of 42 other Heart Failure With Preserved Ejection Fraction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Heart Failure With Preserved Ejection Fraction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)
RECRUITING · NA
-
Ketogenic Diet vs Mixed Diet in Patients With Heart Failure
RECRUITING · NA
-
Pilot Study Lp299v Supplementation in Chronic Heart Failure
RECRUITING · NA
-
Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction
RECRUITING · NA
-
Transitions of Care Clinic (TOCC)
RECRUITING · NA
-
Targeting Breathing Limitations to Improve Functional Outcomes in HFpEF
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI